How Do Hospitals Prevent High-Dose Methotrexate Toxicity?
At a Glance
Hospitals reduce high-dose methotrexate toxicity with continuous IV fluids, sodium bicarbonate to keep urine alkaline, scheduled methotrexate and creatinine tests, and leucovorin rescue. Delayed clearance may require adjusted treatment or glucarpidase.
In this answer
6 sections
When you receive high-dose methotrexate for cancer, your care team follows a strict, highly coordinated hospital protocol to protect your body, specifically your kidneys, from toxicity. Because high doses of this chemotherapy drug are mostly cleared from your body through your kidneys, it can form microscopic crystals in the urine or cause kidney damage if it moves too slowly [1]. To prevent this, the hospital will use a multi-step approach: intravenous (IV) fluids to keep you hydrated, medication to make your urine less acidic, frequent blood tests to check how fast your body is clearing the drug, and a protective “rescue” drug to shield your healthy cells.
IV Fluids (Hyperhydration)
The first step in protecting your kidneys is giving you a large amount of IV fluids before, during, and after your methotrexate infusion [1]. This process, called hyperhydration, keeps your kidneys continually flushed and prevents the methotrexate from becoming too concentrated in your urine [1][2]. You will likely receive fluids at a fast, continuous rate [3]. If your blood tests show that your kidneys are clearing the drug slower than expected, your care team might adjust these fluids to help your body process the medication [4][2].
Important Note on Fluids: Because you will be receiving large amounts of IV fluids, the team will closely monitor your weight, blood pressure, and urine output. You should immediately use your call bell to tell your nurse if you have trouble urinating, notice new swelling or rapid weight gain, or feel short of breath, as these can be signs of fluid overload. Do not try to drink extra water or alter your fluid intake without your team’s approval.
Making the Urine Alkaline (Sodium Bicarbonate)
Methotrexate can easily form tiny crystals in the kidneys if your urine is too acidic. To reduce this risk, your care team will add sodium bicarbonate to your IV fluids or give it to you as an oral medication [5][6]. This makes your urine more alkaline (less acidic).
Nurses will frequently test your urine’s pH level (its acidity) using a dipstick or lab test [5]. Depending on the specific hospital protocol, the goal is often to keep your urine pH at 7.0 or higher [7][8]. If your urine pH drops below your target zone, the team will give you more sodium bicarbonate [5]. Often, your care team will not even begin the methotrexate infusion until your urine has reached this alkaline target [9].
Frequent Blood Monitoring
Your care team needs to know exactly how quickly your body is eliminating the methotrexate. Nurses will draw your blood to check your serum methotrexate levels (how much drug remains in your blood) and your creatinine levels (a marker of how well your kidneys are working) [10][11].
These blood draws happen at precise intervals depending on your specific regimen—commonly checking levels 24, 48, and 72 hours after the start of your infusion, though some protocols test more frequently (such as at 36 or 42 hours) [10][12]. Because everyone clears the drug at a different rate, these exact, timed blood tests are crucial to guide the next steps of your care. Monitoring continues daily until the methotrexate level drops below a very low threshold determined by your protocol [12]. Later tests remain vital even if earlier ones look normal [13].
Leucovorin Rescue
After the methotrexate infusion, the hospital will give you a “rescue” medication called leucovorin (or folinic acid). Unlike an antidote that neutralizes or breaks down the chemotherapy, leucovorin works by providing your healthy cells with an active form of folate, rescuing them from the toxic effects of the methotrexate [2].
Your care team will start leucovorin at a planned, time-critical point—often 24 to 42 hours after the methotrexate infusion begins, depending on your protocol [14][5]. The exact dose you receive, and how long you need to keep taking it, will be adjusted based on your daily blood tests, kidney function, and clinical status [15][16].
What Happens If Clearance is Delayed?
Occasionally, the kidneys clear the drug slower than expected. If your timed methotrexate levels or creatinine indicate a delay, your care team will follow a specific escalation plan, which may include adjusting your hydration and increasing your dose of leucovorin [2].
In cases of severely delayed clearance and significant kidney stress, specialists may decide to use a specialized medication called glucarpidase [17][18]. Glucarpidase acts as an enzyme that rapidly breaks down the methotrexate circulating in your blood so your kidneys don’t have to process it [19]. It is a time-sensitive, specialized treatment that requires careful coordination with your leucovorin schedule [20].
Medication Safety
Many common medications can interfere with your body’s ability to clear methotrexate or increase the risk of kidney problems [1]. These include nonsteroidal anti-inflammatory drugs (NSAIDs like ibuprofen or naproxen), proton-pump inhibitors (acid reflux medications), and certain antibiotics like trimethoprim-sulfamethoxazole. Always provide your team with a complete list of all prescriptions, over-the-counter medicines, and supplements, and never start or stop taking any medication without their direct approval.
Common questions in this guide
How do hospitals protect the kidneys during high-dose methotrexate treatment?
Why are IV fluids and sodium bicarbonate used with methotrexate?
What blood tests are used to monitor high-dose methotrexate?
What is leucovorin rescue, and when is it given?
What happens if methotrexate is clearing from the body too slowly?
Which medicines can interfere with high-dose methotrexate clearance?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific urine pH level will we be targeting, and what methotrexate level do I need to reach before I can be discharged?
- 2.At what specific times will my blood be drawn, and when will my first leucovorin dose be given?
- 3.Are there any of my daily medications or supplements (including over-the-counter drugs) that I should stop taking to ensure my kidneys clear the chemotherapy efficiently?
- 4.How will you monitor me for fluid overload during the intense hydration phase?
- 5.What is your protocol if my methotrexate levels are clearing slower than expected?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (20)
- 1
Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC, McCormick J, Pui CH, et al.
The oncologist 2016; (21(12)):1471-1482 doi:10.1634/theoncologist.2015-0164.
PMID: 27496039 - 2
A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment.
Bielack SS, Soussain C, Fox CP, et al.
Journal of cancer research and clinical oncology 2024; (150(10)):441 doi:10.1007/s00432-024-05945-6.
PMID: 39356310 - 3
High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance.
Chen AR, Wang YM, Lin M, Kuo DJ
Cureus 2020; (12(6)):e8674 doi:10.7759/cureus.8674.
PMID: 32699674 - 4
Feasibility of an oral hydration regimen post high-dose methotrexate in children with acute leukemia: a pilot study.
Karri PS, Sidhique Pr R, Meena JP, et al.
Discover oncology 2026; (17(1)).
PMID: 41661503 - 5
Experience with ambulatory high-dose methotrexate administration as CNS prophylaxis in patients with non-Hodgkin lymphoma.
Pampín R, Labeaga Y, Rodríguez B, et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020; (26(3)):549-555 doi:10.1177/1078155219852412.
PMID: 31156052 - 6
Oral regimen for high dose methotrexate urine alkalinization: a systematic review and meta-analysis.
Kaveh-Ahangaran R, Abdollahi M, Vaezi M, et al.
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 2024; (32(1)):353-377 doi:10.1007/s40199-023-00499-3.
PMID: 38233724 - 7
Risk factors for high-dose methotrexate-induced nephrotoxicity.
Kawaguchi S, Fujiwara SI, Murahashi R, et al.
International journal of hematology 2021; (114(1)):79-84 doi:10.1007/s12185-021-03132-8.
PMID: 33743109 - 8
Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA, Wentzell JR, Giguère P, et al.
Pharmacotherapy 2017; (37(6)):684-691 doi:10.1002/phar.1935.
PMID: 28394433 - 9
Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage.
Visage R, Kaiser N, Williams M, Kim A
Journal of pediatric hematology/oncology 2019; (41(5)):371-375 doi:10.1097/MPH.0000000000001348.
PMID: 30475303 - 10
Urine Methotrexate Concentration at 46-48 Hours Post-Treatment Reflects Methotrexate-Induced Acute Kidney Injury.
Greenmyer JR, Burd L, Kobrinsky NL
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2021; (26(3)):300-305 doi:10.5863/1551-6776-26.3.300.
PMID: 33833633 - 11
Pharmacokinetics and Monitoring of Methotrexate in Adults with Acute Lymphoblastic Leukaemia: A 10-Year Follow-Up at an Italian Centre.
Calabrò PF, Biso L, Lastella M, et al.
Journal of clinical medicine 2025; (14(20)) doi:10.3390/jcm14207400.
PMID: 41156269 - 12
Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
Wippel B, Gundle KR, Dang T, et al.
Cancer medicine 2019; (8(1)):111-116 doi:10.1002/cam4.1898.
PMID: 30580500 - 13
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Ranchon F, Vantard N, Henin E, et al.
Hematological oncology 2018; (36(2)):399-406 doi:10.1002/hon.2479.
PMID: 28983943 - 14
A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients.
Peng C, Li X, Huang H, et al.
Leukemia & lymphoma 2020; (61(8)):1842-1849 doi:10.1080/10428194.2020.1747061.
PMID: 32316801 - 15
A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S, Srinivasan HN, Joseph LL, et al.
Pediatric hematology and oncology 2021; (38(5)):434-443 doi:10.1080/08880018.2020.1863535.
PMID: 33764242 - 16
Delayed Elimination Concentrations of High-Dose Methotrexate in Adults With Hematological Malignancies: To Standardize or Not? A Scoping Review.
T F, Goh AS, Mohamed Shah N, et al.
Therapeutic drug monitoring 2026; (48(4)):432-442 doi:10.1097/FTD.0000000000001401.
PMID: 41252654 - 17
Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey LB, Balis FM, O'Brien MM, et al.
The oncologist 2018; (23(1)):52-61 doi:10.1634/theoncologist.2017-0243.
PMID: 29079637 - 18
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
Heuschkel S, Kretschmann T, Teipel R, et al.
Cancer chemotherapy and pharmacology 2022; (89(1)):41-48 doi:10.1007/s00280-021-04361-8.
PMID: 34669022 - 19
Glucarpidase efficacy in mitigating methotrexate toxicity is unaffected by concurrent administration of folinic acid.
Wahlestedt M, Hansson K, Bill A, et al.
Cancer chemotherapy and pharmacology 2026; (96(1)).
PMID: 42101491 - 20
DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity.
Young A, Beriault D, Jung B, et al.
Canadian journal of kidney health and disease 2019; (6()):2054358119895078 doi:10.1177/2054358119895078.
PMID: 31903191
This page explains hospital safeguards during high-dose methotrexate infusions for informational purposes only and does not constitute medical advice. Your oncology team should direct your fluids, medications, monitoring, and any rescue treatment.
Get notified when new evidence is published on Methotrexate toxicity.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.